cognitive
Treatment of Cognitive Impairment in Schizophrenia
Impairments in everyday functional outcomes are very common in people with schizophrenia and these impairments are associated with deficits in cognitive functioning. Cognitive enhancement has been proposed as a pathway to disability reduction. This pathway has been clearly defined in terms of the required clinical trials methods, with primary (cognitive) and secondary (functional) outcome measures well validated. Second generation (Newer, Atypical) antipsychotic medications have been thoroughly evaluated with their cognitive enhancement potential. Read more about this session.
Genetic associations between neuregulin-1 SNPs and neurocognitive function in multigenerational, multiplex schizophrenia families
Objectives: Recent work shows promising associations between schizophrenia and polymorphisms in neuregulin-1 (NRG1) and a large literature also finds strong familial relationships between schizophrenia and cognitive deficits.
Effects of Drug Burden Index on Cognitive Function in Older Men
Abstract: We aimed to assess the relationship between Drug Burden Index (DBI), a risk assessment tool that measures anticholinergic and sedative medication exposure and cognitive performance, and cognitive impairment in older people. The study population consisted of community-dwelling older men, 70 years or older, living in Sydney, Australia. The Addenbrooke’s Cognitive Examination (ACE) and the Trail Making Task (TMT) cognitive tests were performed, and participants were categorized as having intact cognition, mild cognitive impairment, or dementia using clinical diagnostic criteria.
COMT Val158Met Genotype Determines the Direction of Cognitive Effects Produced by Catechol-O-Methyltransferase Inhibition
Background:
Catechol-O-methyltransferase (COMT) metabolizes dopamine. The COMT Val158Met polymorphism influences its activity, and multiple neural correlates of this genotype on dopaminergic phenotypes, especially working memory, have been reported. COMT activity can also be regulated pharmacologically by COMT inhibitors.
Psychometric validation and clinical validity of the Minor Melancholia Mood Checklist (MMCL-32)
Publication year: 2012Source:Journal of Affective Disorders, Volume 137, Issues 1–3P. Bech, E.M. Christensen, M. Vinberg, G. Bech-Andersen, L.V. Kessing
Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers
Publication year: 2012Source:Journal of Affective Disorders, Volume 137, Issues 1–3Izabela Guimarães Barbosa, Natalia Pessoa Rocha, Rodrigo Barreto Huguet, Rodrigo A. Ferreira, João Vinícius Salgado, Livia A. Carvalho, Carmine M. Pariante, Antônio Lúcio Teixeira
Is it possible to have impaired neurocognition but good social cognition in schizophrenia?
Publication year: 2012Source:Schizophrenia Research, Volume 135, Issues 1–3Jennifer R. Fanning, Morris D. Bell, Joanna M. Fiszdon
Clinical and cognitive correlates of insight in first-episode schizophrenia
Publication year: 2012Source:Schizophrenia Research, Volume 135, Issues 1–3Sherry K.W. Chan, Kevin K.S. Chan, May M.L. Lam, Cindy P.Y. Chiu, Christy L.M. Hui, Gloria H.Y. Wong, W.C. Chang, Eric Y.H. Chen
Effects of acute combined serotonin and dopamine depletion on cue-induced drinking intention/desire and cognitive function in patients with alcohol dependence
Publication year: 2012Source:Drug and Alcohol DependenceHong-Qiang Sun, Yu Liu, Peng Li, Yan-Ping Bao, Li-Xia Sheng, Rui-Ling Zhang, Yan-Jun Cao, Xiao-Lan Di, Fu-De Yang, Fan Wang, Yi-Xiao Luo, Lin Lu